Resistance to neoadjuvant talazoparib in triple-negative breast cancer by BRN2-induced ATR/STAT3 pathways or SHLD2 subclone expansion

Proceedings of the National Academy of Sciences, Volume 123, Issue 16, April 2026. <br/>SignificanceImproved safety profiles of newer generation selective poly(ADP-ribose) polymerase inhibitors support their expanded use in the neoadjuvant setting. To optimize clinical benefit, it is critical to identify resistance mechanisms to predict …